Table 2.
Biopathological characteristics
| Total (pT1a and pT1b) | pT1a | pT1b | |
|---|---|---|---|
|
N. of patients |
402 |
82 |
320 |
|
Histology |
|
|
|
| Ductal |
336 (83.6%) |
70 (85.4%) |
266 (83.1%) |
| Lobular |
38 (9.5%) |
7 (8.5%) |
31 (9.7%) |
| Mixed |
5 (1.2%) |
0 (0.0%) |
5 (1.6%) |
| Other |
23 (5.7%) |
5 (6.1%) |
18 (5.6%) |
|
Vascular invasion |
|
|
|
| Yes |
30 (7.5%) |
3 (3.7%) |
27 (8.4%) |
| No |
267 (66.4%) |
51 (62.2%) |
216 (67.5%) |
| Unknown |
105 (26.1%) |
28 (34.1%) |
77 (24.1%) |
|
Grading |
|
|
|
| G1 |
101 (25.1%) |
18 (22.0%) |
83 (25.9%) |
| G2 |
221 (55.0%) |
46 (56.1%) |
175 (54.7%) |
| G3 |
72 (17.9%) |
15 (18.3%) |
57 (17.8%) |
| Unknown |
8 (2.0%) |
3 (3.7%) |
5 (1.6%) |
|
Proliferation index (Ki-67/MB1) |
|
|
|
| 0–18% |
283 (70.5%) |
53 (64.6%) |
230 (71.8%) |
| 19–29% |
52 (12.9%) |
17 (20.7%) |
35 (10.9%) |
| ≥ 30% |
54 (13.4%) |
7 (8.5%) |
47 (14.7%) |
| Unknown |
13 (3.2%) |
5 (6.1%) |
8 (2.5%) |
|
ER status |
|
|
|
| ER positive (≥ 10%) |
351 (87.3%) |
65 (80.5%) |
285 (89.1%) |
| ER negative (0–9%) |
51 (12.7%) |
16 (19.5%) |
35 (10.9%) |
|
PgR status |
|
|
|
| PgR positive (≥ 10%) |
300 (74.6%) |
54 (65.9%) |
246 (76.9%) |
| PgR negative (0–9%) |
102 (25.4%) |
28 (34.1%) |
74 (23.1%) |
|
Hormonal status* |
|
|
|
| ER and/or PgR positive |
354 (88.1%) |
65 (81.7%) |
287 (89.7%) |
| ER and PgR negative |
48 (11.9%) |
15 (18.3%) |
33 (10.3%) |
|
HER2 status** |
|
|
|
| Positive |
49 (12.2%) |
19 (23.2%) |
30 (9.3%) |
| Negative |
344 (85.6%) |
62 (75.6%) |
282 (88.2%) |
| Unknown |
9 (2.2%) |
1 (1.2%) |
8 (2.5%) |
|
pN status |
|
|
|
| pN0 |
319 (79.4%) |
67 (81.7%) |
252 (78.8%) |
| pN1 (1–3) |
74 (18.4%) |
12 (14.6%) |
62 (19.4%) |
| pN2 (4–9) |
6 (1.5%) |
2 (2.4%) |
4 (1.3%) |
| pN3 (≥ 10) | 3 (0.7%) | 1 (1.2%) | 2 (0.6%) |
* cut off: 10%
** HER2 status positive if: IHC 3+; or IHC 2+ and amplified by FISH,SISH,CISH; or amplified by FISH,SISH,CISH